Briacell enrollment pace accelerating in phase 3 clinical study in advanced metastatic breast cancer (bria-abc)

Over 75 patients enrolled in briacell's pivotal phase 3 study of bria-imt ™ plus immune check point inhibitor in metastatic breast cancer (mbc) 54 clinical sites across 15 states currently enrolling patients including sylvester comprehensive cancer center, cancer care northwest, hematology oncology associates of fredericksburg, northwestern university, manhattan hematology/oncology associates, new york cancer and bood specialists, and texas oncology-baylor charles a. sammons cancer center philadelphia and vancouver, british columbia, april 22, 2025 (globe newswire) -- briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell” or the “company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that its ongoing pivotal phase 3 clinical study (listed on clinicaltrials.gov as nct06072612) has consented over 100 and has enrolled over 75 patients.
ABC Ratings Summary
ABC Quant Ranking